Comparing monitoring vs early treatment for ANCA-positive vasculitis
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with GPA or MPA.
- You have been on rituximab maintenance treatment for at least 18 months (receiving 500 mg infusions every 6 months for a total of 4–5 doses).
- Your disease is currently in complete remission (no active symptoms).
- Your ANCA test turned positive again in the past 3 months.
- You agree to use effective birth control if needed and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial tests a new treatment called CT1192 for a type of blood vessel inflammation called ANCA-associated vasculitis. It is for people whose standard treatments have not worked or whose disease has come back. The goal is to see if CT1192 is safe and helps control the disease.
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
Hear when a new Microscopic Polyangiitis (MPA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.